In the present study, we considered the GRA16/PP2A-B55/AKT/NF-κB pathway as an anticancer target and established a stable model expressing GRA16 using H1299 cells, which are p53-null NSCLC cells. This evidence concerns the gene TP53 and non-small cell lung carcinoma.